Benefit-risk assessment of levetiracetam in the treatment of partial seizures

Drug Safety

Volumn 28, Issue 10, 2005, Pages 871-890

  Abou Khalil, Bassel ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CYTOCHROME P450; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PLACEBO; TOPIRAMATE;

AGGRESSION; AGITATION; ALLERGIC REACTION; ANGER; ANOREXIA; ANXIETY; ASTHENIA; BEHAVIOR DISORDER; BRAIN SURGERY; BREAST FEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CONVULSION; DELUSION; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTOXICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG URINE LEVEL; DYSPEPSIA; ERYTHROCYTE COUNT; EUPHORIA; FLU LIKE SYNDROME; FOCAL EPILEPSY; GENERALIZED EPILEPSY; GERIATRICS; HALLUCINATION; HEADACHE; HOSTILITY; HUMAN; HYPERACTIVITY; INFECTION; INJURY; IRRITABILITY; LANDAU KLEFFNER SYNDROME; LEARNING DISORDER; LENNOX GASTAUT SYNDROME; LEUKOCYTE COUNT; LOBECTOMY; MENTAL INSTABILITY; META ANALYSIS; MOOD DISORDER; NERVOUSNESS; ONSET AGE; OPEN STUDY; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZATION; RASH; RETROSPECTIVE STUDY; REVIEW; RHINITIS; RISK ASSESSMENT; SEDATION; SOMNOLENCE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TERATOGENICITY; TREMOR;

ADULT; AGED; ANTICONVULSANTS; CHILD; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ECONOMICS, PHARMACEUTICAL; EPILEPSIES, PARTIAL; HUMANS; PIRACETAM; QUALITY OF LIFE; RISK ASSESSMENT;

EID: 26444433365     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200528100-00004     Document Type: Review

References (118)

1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993; 34 (3): 453-68
2. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981; 22 (4): 489-501
3. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342 (5): 314-9
4. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000; 85 (2): 77-85
5. Patsalos PN. The pharmacokinetic characteristics of levetiracetam. Methods Find Exp Clin Pharmacol 2003; 25 (2): 123-9
6. Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia 2001; 42 Suppl. 4: 24-7
7. French J. Use of levetiracetam in special populations. Epilepsia 2001; 42 Suppl. 4: 40-3
8. Nicolas JM, Collart P, Gerin B, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new an-tiepileptic agent. Drug Metab Dispos 1999; 27 (2): 250-4
9. Browne TR, Szabo GK, Leppik IE, et al. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J Clin Pharmacol 2000; 40 (6): 590-5
10. Coupez R, Nicolas JM, Browne TR. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia 2003; 44 (2): 171-8
11. Levy RH, Ragueneau-Majlessi I, Baltes E. Repeated administra-tion of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res 2001; 46 (2): 93-9
12. Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res 2001; 47 (1-2): 55-63
13. Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 2002; 43 (7): 697-702
14. Abou-Khalil B, Hemdal P, Privitera MD. An open-label study of levetiracetam at individualised doses between 1000 and 3000mg day (-1) in adult patients with refractory epilepsy. Seizure 2003; 12 (3): 141-9
15. May TW, Rambeck B, Jurgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 2003; 25 (6): 690-9
16. Perucca E, Gidal BE, Baltes E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res 2003; 53 (1-2): 47-56
17. Pellock JM, Glauser TA, Bebin EM, et al. Pharmacokinetic study of levetiracetam in children. Epilepsia 2001; 42 (12): 1574-9
18. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55 (2): 236-42
19. Privitera M. Efficacy of levetiracetam: a review of three pivotal clinical trials. Epilepsia 2001; 42 Suppl. 4: 31-5
20. French J, Arrigo C. Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia 2005; 46 (2): 324-6
21. Shorvon SD, Lowenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000; 41 (9): 1179-86
22. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000; 41 (10): 1276-83
23. Leppik I, Morrell M, Godfroid P, et al. Seizure-free days observed in randomized placebo-controlled add-on trials with levetiracetam in partial epilepsy. Epilepsia 2003; 44 (10): 1350-2
24. Glauser TA, Gauer LJ, Chen L, et al. Multicenter, double-blind, placebo-controlled trial of adjunctive levetiracetam (Keppra.) therapy (up to 60 mg/kg/day) in pediatric patients with refractory partial epilepsy [abstract]. Epilepsia 2004; 45 Suppl. 7: 186
25. Boon P, Chauvel P, Pohlmann-Eden B, et al. Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res 2002; 48 (1-2): 77-89
26. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000mg daily and 4000mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9 (2): 80-7
27. Sharief M, Singh P, Sander J, et al. Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy. J Epilepsy 1996; 9: 106-12
28. Grant R, Shorvon SD. Efficacy and tolerability of 1000-4000mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Res 2000; 42 (2-3): 89-95
29. Beran RG, Berkovic SF, Black AB, et al. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Epilepsy Res 2005; 63 (1): 1-9
30. Mohanraj R, Parker PG, Stephen LJ, et al. Levetiracetam in refractory epilepsy: a prospective observational study. Seizure 2005; 14 (1): 23-7
31. Morrell MJ, Leppik I, French J, et al. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 2003; 54 (2-3): 153-61
32. Ferrendelli JA, French J, Leppik I, et al. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav 2003; 4 (6): 702-9
33. Bazil CW, Rose A, Resor S, et al. Levetiracetam may be more effective for late-onset partial epilepsy. Arch Neurol 2002; 59 (12): 1905-8
34. DeToledo JC. Changing presentation of seizures with aging: clinical and etiological factors. Gerontology 1999; 45 (6): 329-35
35. Alsaadi TM, Koopmans S, Apperson M, et al. Levetiracetam monotherapy for elderly patients with epilepsy. Seizure 2004; 13 (1): 58-60
36. Alsaadi TM, Thieman C. Levetiracetam monotherapy for newly diagnosed epilepsy patients. Seizure 2003; 12 (3): 154-6
37. Alsaadi TM, Thieman C, Zusman EE. Levetiracetam monotherapy for adults with localization-related epilepsy. Epilepsy Behav 2002; 3 (5): 471-4
38. Motamedi M, Nguyen DK, Zaatreh M, et al. Levetiracetam efficacy in refractory partial-onset seizures, especially after failed epilepsy surgery. Epilepsia 2003; 44 (2): 211-4
39. Janszky J, Pannek HW, Janszky I, et al. Failed surgery for temporal lobe epilepsy: predictors of long-term seizure-free course. Epilepsy Res 2005; 64 (1-2): 35-44
40. Glauser TA, Pellock JM, Bebin EM, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 2002; 43 (5): 518-24
41. Lagae L, Buyse G, Deconinck A, et al. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur J Paediatr Neurol 2003; 7 (3): 123-8
42. De Los Reyes EC, Sharp GB, Williams JP, et al. Levetiracetam in the treatment of Lennox-Gastaut syndrome. Pediatr Neurol 2004; 30 (4): 254-6
43. Kossoff EH, Boatman D, Freeman JM. Landau-Kleffner syndrome responsive to levetiracetam. Epilepsy Behav 2003; 4 (5): 571-5
44. Capovilla G, Beccaria F, Cagdas S, et al. Efficacy of levetiracetam in pharmacoresistant continuous spikes and waves during slow sleep. Acta Neurol Scand 2004; 110 (3): 144-7
45. Coppola G, Mangano S, Tortorella G, et al. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy. Epilepsy Res 2004; 59 (1): 35-42
46. Wheless JW, Ng YT. Levetiracetam in refractory pediatric epilepsy. J Child Neurol 2002; 17 (6): 413-5
47. Tan MJ, Appleton RE. Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience. Seizure 2004; 13 (3): 142-5
48. Kasteleijn-Nolst Trenite DG, Marescaux C, Stodieck S, et al. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996; 25 (3): 225-30
49. Krauss GL, Betts T, Abou-Khalil B, et al. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure 2003; 12 (8): 617-20
50. Cavitt J, Privitera M. Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence. Arch Neurol 2004; 61 (10): 1604-7
51. Cohen J. Levetiracetam monotherapy for primary generalised epilepsy. Seizure 2003; 12 (3): 150-3
52. Gallagher MJ, Eisenman LN, Brown KM, et al. Levetiracetam reduces spike-wave density and duration during continuous EEG monitoring in patients with idiopathic generalized epilepsy. Epilepsia 2004; 45 (1): 90-1
53. Nakken KO, Eriksson AS, Lossius R, et al. A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy. Seizure 2003; 12 (1): 42-6
54. Loscher W, Honack D. Development of tolerance during chronic treatment of kindled rats with the novel antiepileptic drug levetiracetam. Epilepsia 2000; 41 (12): 1499-506
55. Krakow K, Walker M, Otoul C, et al. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 2001; 56 (12): 1772-4
56. Ben-Menachem E, Edrich P, Van Vleymen B, et al. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res 2003; 53 (1-2): 57-64
57. Abou-Khalil B, Lazenby B. Long-term experience with levetiracetam. Epileptic Disord 2003; 5 Suppl. 1: S33-7
58. Betts T, Yarrow H, Greenhill L, et al. Clinical experience of marketed levetiracetam in an epilepsy clinic: a one year follow up study. Seizure 2003; 12 (3): 136-40
59. Ben-Menachem E, Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 2003; 12 (3): 131-5
60. Nicolson A, Lewis SA, Smith DF. A prospective analysis of the outcome of levetiracetam in clinical practice. Neurology 2004; 63 (3): 568-70
61. Loscher W, Honack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 1993; 232 (2-3): 147-58
62. Klitgaard H, Matagne A, Gobert J, et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998; 353 (2-3): 191-206
63. Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998; 284 (2): 474-9
64. Matagne A, Klitgaard H. Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man. Epilepsy Res 1998; 31 (1): 59-71
65. Zona C, Niespodziany I, Marchetti C, et al. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 2001; 10 (4): 279-86
66. Klitgaard H, Pitkanen A. Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord 2003; 5 Suppl. 1: S9-16
67. Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002; 136 (5): 659-72
68. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca (2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 2001; 306 (1-2): 5-8
69. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002; 43 (1): 9-18
70. Noyer M, Gillard M, Matagne A, et al. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995; 286 (2): 137-46
71. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004; 101 (26): 9861-6
72. Miller GS. Efficacy and safety of levetiracetam in pediatric migraine. Headache 2004; 44 (3): 238-43
73. Troost B, Wiles R. Two-phase open-label study of levetiracetam in the management of intractable headache. Paper presented at Diamond Headache Meeting; Rancho Mirage (CA) 2003
74. Frucht SJ, Louis ED, Chuang C, et al. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001; 57 (6): 1112-4
75. Genton P, Gelisse P. Antimyoclonic effect of levetiracetam. Epileptic Disord 2000; 2 (4): 209-12
76. Genton P, Gelisse P. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001; 57 (6): 1144-5
77. Imperiale D, Bortolotto S, Cucatto A, et al. Levetiracetam control of myoclonus in a patient with Creutzfeldt-Jakob disease. Eur Neurol 2003; 49 (3): 189-90
78. Keswani SC, Kossoff EH, Krauss GL, et al. Amelioration of spinal myoclonus with levetiracetam. J Neurol Neurosurg Psychiatry 2002; 73 (4): 457-8
79. Krauss GL, Bergin A, Kramer RE, et al. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001; 56 (3): 411-2
80. Magaudda A, Gelisse P, Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg dis-ease: clinical observations. Epilepsia 2004; 45 (6): 678-81
81. Schauer R, Singer M, Saltuari L, et al. Suppression of cortical myoclonus by levetiracetam. Mov Disord 2002; 17 (2): 411-5
82. Lim LL, Ahmed A. Limited efficacy of levetiracetam on myoclonus of different etiologies. Parkinsonism Relat Disord 2005; 11 (2): 135-7
83. Handforth A, Martin FC. Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. Mov Disord 2004; 19 (10): 1215-21
84. Sullivan KL, Hauser RA, Zesiewicz TA. Levetiracetam for the treatment of essential tremor [letter]. Mov Disord 2005; 20 (5): 640
85. Ondo WG, Jimenez JE, Vuong KD, et al. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol 2004; 27 (6): 274-7
86. Bushara KO, Malik T, Exconde RE. The effect of levetiracetam on essential tremor. Neurology 2005; 64 (6): 1078-80
87. Rowbotham MC, Manville NS, Ren J. Pilot tolerability and effectiveness study of levetiracetam for postherpetic neuralgia. Neurology 2003; 61 (6): 866-7
88. Price MJ. Levetiracetam in the treatment of neuropathic pain: three case studies. Clin J Pain 2004; 20 (1): 33-6
89. Hawker K, Frohman E, Racke M. Levetiracetam for phasic spasticity in multiple sclerosis. Arch Neurol 2003; 60 (12): 1772-4
90. Simon NM, Worthington JJ, Doyle AC, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 2004; 65 (9): 1219-22
91. Grunze H, Langosch J, Born C, et al. Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J Clin Psychiatry 2003; 64 (7): 781-4
92. Braunig P, Kruger S. Levetiracetam in the treatment of rapid cycling bipolar disorder. J Psychopharmacol 2003; 17 (2): 239-41
93. Post RM, Altshuler LL, Frye MA, et al. Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. J Clin Psychiatry 2005; 66 (3): 370-4
94. Rugino TA, Samsock TC. Levetiracetam in autistic children: an open-label study. J Dev Behav Pediatr 2002; 23 (4): 225-30
95. French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 2001; 47 (1-2): 77-90
96. Cramer JA, De Rue K, Devinsky O, et al. A systematic review of the behavioral effects of levetiracetam in adults with epilep-sy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003; 4 (2): 124-32
97. Brodtkorb E, Klees TM, Nakken KO, et al. Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects. Epilepsy Behav 2004; 5 (2): 231-5
98. Mula M, Trimble MR, Yuen A, et al. Psychiatric adverse events during levetiracetam therapy. Neurology 2003; 61 (5): 704-6
99. Mula M, Trimble MR, Sander JW. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure 2004; 13 (1): 55-7
100. Dinkelacker V, Dietl T, Widman G, et al. Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy Behav 2003; 4 (5): 537-47
101. White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology 2003; 61 (9): 1218-21
102. Lagae L, Buyse G, Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: an add-on and monotherapy trial. Seizure 2005; 14 (1): 66-71
103. Kossoff EH, Bergey GK, Freeman JM, et al. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001; 42 (12): 1611-3
104. Youroukos S, Lazopoulou D, Michelakou D, et al. Acute psychosis associated with levetiracetam. Epileptic Disord 2003; 5 (2): 117-9
105. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62 (8): 1252-60
106. Cramer JA, Arrigo C, Van Hammee G, et al. Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group. Epilepsia 2000; 41 (7): 868-74
107. Gidal BE, Sheth RD, Magnus L, et al. Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. Epilepsy Res 2003; 56 (2-3): 121-6
108. Cramer JA, Leppik IE, Rue KD, et al. Tolerability of levetiracetam in elderly patients with CNS disorders. Epilepsy Res 2003; 56 (2-3): 135-45
109. Isoherranen N, Spiegelstein O, Bialer M, et al. Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity. Epilepsia 2003; 44 (10): 1280-8
110. Long L. Levetiracetam monotherapy during pregnancy: a case series. Epilepsy Behav 2003; 4 (4): 447-8
111. ten Berg K, Samren EB, van Oppen AC, et al. Levetiracetam use and pregnancy outcome. Reprod Toxicol 2005; 20 (1): 175-8
112. Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia 2005; 46 (5): 775-7
113. Barrueto Jr F, Williams K, Howland MA, et al. A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data. J Toxicol Clin Toxicol 2002; 40 (7): 881-4
114. Paul F, Meencke HJ. Levetiracetam in focal epilepsy and hepatic porphyria: a case report. Epilepsia 2004; 45 (5): 559-60
115. Wilby J, Kainth A, Hawkins N, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 2005; 9 (15): 1-172
116. Sheehy O, St-Hilaire JM, Bernier G, et al. Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy. Pharmacoeconomics 2005; 23 (5): 493-503
117. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62 (8): 1261-73
118. Marson AG, Hutton JL, Leach JP, et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resis tant localization-related epilepsy: a systematic review. Epilepsy Res 2001; 46 (3): 259-70.